세계의 핵의학/방사성의약품 시장 규모 : 용도별, 시술 수별, 유형별, 지역별, 범위 및 예측

Global Nuclear Medicine/Radiopharmaceuticals Market Size By Application, By Procedural Volume, By Type, By Geographic Scope And Forecast

US $ 3,950 ￦ 5,415,000

PDF (Single User License)

PDF 보고서를 1명만 이용할 수 있는 라이선스입니다. 보고서의 다운로드와 인쇄가 가능합니다.

US $ 4,850 ￦ 6,649,000

PDF & Excel (5 User License)

PDF 및 Excel 보고서를 동일 기업의 5명까지 이용할 수 있는 라이선스입니다. 보고서의 다운로드와 인쇄가 가능합니다.

US $ 7,550 ￦ 10,351,000

PDF & Excel (Enterprise User License)

PDF 및 Excel 보고서를 동일기업내 모든 분들이 이용할 수 있는 라이선스입니다. 보고서의 다운로드와 인쇄가 가능합니다.

한글목차

핵의학/방사성의약품 시장 규모 및 전망

핵의학/방사성의약품 시장 규모는 2020년 65억 6,000만 달러로 평가되며, 2021년부터 2028년까지 연평균 9.47% 성장하여 2028년에는 135억 3,000만 달러에 달할 것으로 예상됩니다.

신경학 분야에서 방사성의약품에 대한 수요가 예측 기간 동안 핵의학/방사성의약품 시장의 성장을 촉진할 것입니다. 핵의학/방사성의약품 세계 시장 보고서는 시장의 전반적인 평가를 제공합니다. 주요 부문, 동향, 시장 촉진요인, 억제요인, 경쟁 상황, 시장에서 중요한 역할을 하는 요인 등을 포괄적으로 분석합니다.

세계 핵의학/방사성의약품 시장의 정의

진단 목적으로 환자에게 투여되고 특정 영상 진단 장비를 통해 모니터링되는 방사성 화합물을 방사성의약품이라고 합니다. 방사성의약품은 치료 및 진단 목적으로 사용됩니다. 방사성의약품은 주로 유기 분자에 방사성 동위원소를 결합시킨 것입니다. 지난 50년 동안 핵의학은 화학 분야에 대한 투자 증가와 방사성 핵종 및 방사성 표지 화합물의 개발로 크게 발전해 왔습니다.

핵의학/방사성의약품 세계 시장 개요

핵의학/방사성의약품 세계 시장 성장은 대상 질환의 발생 건수와 유병률 증가에 의해 주도되고 있습니다. 알파선 면역요법에 기반한 표적 암 치료에 대한 수요가 증가하고 있으며, 이에 따라 세계 핵의학/방사성의약품 시장은 빠른 속도로 성장하고 있습니다.

그러나 몇 가지 억제요인이 세계 핵의학/방사성의약품 시장의 성장을 제한하고 있습니다. 방사성의약품의 짧은 수명은 세계 핵의학/방사성의약품 시장의 성장을 후퇴시킬 수 있습니다. 또한, 높은 장비 가격은 세계 핵의학/방사성의약품 시장의 성장을 저해할 수 있습니다.

목차

제1장 세계의 핵의학/방사성의약품 시장 소개

• 시장 개요
• 조사 범위
• 가정

제2장 주요 요약

제3장 VERIFIED MARKET RESEARCH 조사 방법

• 데이터 마이닝
• 밸리데이션
• 1차 자료
• 데이터 소스 리스트

제4장 세계의 핵의학/방사성의약품 시장 전망

• 개요
• 시장 역학
  • 성장 촉진요인
  • 성장 억제요인
  • 기회
• Porter's Five Forces 모델
• 밸류체인 분석

제5장 핵의학/방사성의약품 세계 시장 : 용도별

• 개요
• 진단 용도
  • SPECT 용도
• 기타 SPECT 용도
  • PET 용도
  • 치료 용도
  • 갑상선
  • 골전이
  • 림프종
  • 내분비 종양
  • 기타 치료 용도

제6장 핵의학/방사성의약품 세계 시장 : 시술 수별

• 개요
• 진단 시술
  • SPECT 방사성의약품
  • PET 방사성의약품
• 치료 시술
  • 베타선 이미터
  • 알파 선방출 핵종
  • 근접방사선치료용 아이소토프

제7장 세계의 핵의학/방사성의약품 시장 : 유형별

• 개요
• 진단용 핵의학
  • SPECT 방사성의약품
• PET 방사성의약품
  • F-18
  • 루비듐 82
  • 기타 PET 아이소토프
• 치료용 핵의학/방사성의약품
  • 베타선 방출 핵종
  • 알파선 방출 핵종
  • 근접방사선치료용 아이소토프

제8장 핵의학/방사성의약품 세계 시장 : 지역별

• 개요
• 북미
  • 미국
  • 캐나다
  • 멕시코
• 유럽 지역별
  • 독일
  • 영국
  • 프랑스
  • 기타 유럽
• 아시아태평양
  • 중국
  • 일본
  • 인도
  • 기타 아시아태평양
• 세계 기타 지역
  • 라틴아메리카
  • 중동 및 아프리카

제9장 세계의 핵의학/방사성의약품 시장 경쟁 구도

• 개요
• 각사의 시장 순위
• 주요 개발 전략

제10장 기업 개요

• Cardinal Health, Inc.
• Mallinckrodt PLC
• GE Healthcare(A Fully-Owned Subsidiary of General Electric Company)
• Lantheus Medical Imaging, Inc.
• Bayer AG
• Bracco Imaging S.P.A
• Eczacibasi-Monrol Nuclear Products
• Nordion, Inc.(A Subsidiary of Sterigenics International LLC.)
• Advanced Accelerator Applications S.A.
• Iba Molecular

제11장 부록

• 관련 보고서

ksm

영문 목차

영문목차

Nuclear Medicine/Radiopharmaceuticals Market Size And Forecast

Nuclear Medicine/Radiopharmaceuticals Market size was valued at USD 6.56 Billion in 2020 and is projected to reachUSD 13.53 Billion by 2028, growing at aCAGR of 9.47% from 2021 to 2028.

The demand for radiopharmaceuticals in neurological applications will drive the growth of the Nuclear Medicine/Radiopharmaceuticals Market during the forecast period. The Global Nuclear Medicine/Radiopharmaceuticals Market report provides a holistic evaluation of the market. The report offers a comprehensive analysis of key segments, trends, drivers, restraints, competitive landscape, and factors that are playing a substantial role in the market.

Global Nuclear Medicine/Radiopharmaceuticals Market Definition

The radioactive compounds administered to the patient and monitored via a specific imaging device for diagnostic purposes are known as radiopharmaceuticals. This drug can be used for therapeutic or diagnostic purposes. The radiopharmaceuticals are mainly composed of a radioisotope bond to an organic molecule. Over the last 50 years, nuclear medicine has developed significantly owing to increasing investments in the field of chemistry and the development of radionuclides and radiolabeled compounds.

Global Nuclear Medicine/Radiopharmaceuticals Market Overview

The growth of the global Nuclear Medicine/Radiopharmaceuticals Market is being driven by increasing incidences and prevalence of target conditions. The demand for alpha radioimmunotherapy-based targeted cancer treatment is increasing and owing to which the global Nuclear Medicine/Radiopharmaceuticals Market is flourishing at a rapid pace.

However, some restraints are liming the growth of the global Nuclear Medicine/Radiopharmaceuticals Market. The short life span of radiopharmaceuticals may create setbacks for the growth of the global Nuclear Medicine/Radiopharmaceuticals Market. Also, the high equipment prices may hamper the growth of the global Nuclear Medicine/Radiopharmaceuticals Market.

Global Nuclear Medicine/Radiopharmaceuticals Market: Segmentation Analysis

The Global Nuclear Medicine/Radiopharmaceuticals Market is Segmented on the basis of Application, Procedural Volume, Type, and Geography.

Nuclear Medicine/Radiopharmaceuticals Market, By Application

• 1.1 Diagnostic Applications
  • 1.1.1 SPECT Applications
  • 1.1.1.1 Cardiology
  • 1.1.1.2 Neurology
  • 1.1.1.3 Thyroid
• 1.2 Other SPECT Applications
  • 1.2.1 PET Applications
  • 1.2.1.1 Oncology
  • 1.2.1.2 Cardiology
  • 1.2.1.3 Neurology
  • 1.2.1.4 Other PET Applications
  • 1.2.2 Therapeutic Applications
  • 1.2.3 Thyroid
  • 1.2.4 Bone Metastasis
  • 1.2.5 Lymphoma
  • 1.2.6 Endocrine Tumors
  • 1.2.7 Other Therapeutic Applications

Based on Application, the market is segmented into Diagnostic Applications and Other SPECT Applications. The diagnostic applications dominated the global Nuclear Medicine/Radiopharmaceuticals Market. The SPECT applications especially contributed majorly to the growth of the market.

Nuclear Medicine/Radiopharmaceuticals Market, By Procedural Volume

• 2.1 Diagnostic Procedures
  • 2.1.1 SPECT Radiopharmaceuticals
  • 2.1.2 PET Radiopharmaceuticals
• 2.2 Therapeutic Procedures
  • 2.2.1 Beta Emitters
  • 2.2.2 Alpha Emitters
  • 2.2.3 Brachytherapy Isotopes

Based on Procedural Volume, the market is segmented into Diagnostic Procedures and Therapeutic Procedures. The Diagnostic Procedures are further bifurcated into SPECT Radiopharmaceuticals, PET Radiopharmaceuticals, and Therapeutic Procedures. The Therapeutic Procedures are further bifurcated into Beta Emitters, Alpha Emitters, and Brachytherapy Isotopes. The Diagnostic Procedures dominated the global Nuclear Medicine/Radiopharmaceuticals Market.

Nuclear Medicine/Radiopharmaceuticals Market, By Type

• 3.1 Diagnostic Nuclear Medicine
  • 3.1.1 SPECT Radiopharmaceuticals
  • 3.1.1.1 Tc-99m
  • 3.1.1.2 Tl-201
  • 3.1.1.3 Ga-67
  • 3.1.1.4 I-123
  • 3.1.1.5 Other SPECT Isotopes
• 3.3 PET Radiopharmaceuticals
  • 3.2.1 F-18
  • 3.2.2 Rubidium-82
  • 3.2.3 Other PET Isotopes
• 3.3 Therapeutic Nuclear Medicine/Radiopharmaceuticals
  • 3.3.1 Beta Emitters
  • 3.3.1.1 Iodine-131
  • 3.3.1.2 Y-90
  • 3.3.1.3 Sm-153
  • 3.3.1.4 Re-186
  • 3.3.1.5 Lu-177
  • 3.3.1.6 Other Beta Emitters
  • 3.3.2 Alpha Emitters
  • 3.3.2.1 Ra-223
  • 3.3.3 Brachytherapy Isotopes
  • 3.3.3.1 Iodine-125
  • 3.3.3.2 Iridium-192
  • 3.3.3.3 Palladium-103
  • 3.3.3.4 Cesium-131
  • 3.3.3.5 Other Brachytherapy Isotopes

Based on Type, the market is segmented into Diagnostic Nuclear Medicine, PET Radiopharmaceuticals, and Therapeutic Nuclear Medicine/Radiopharmaceuticals. The Therapeutic Nuclear Medicine/ Radiopharmaceuticals is further bifurcated into Beta Emitters, Alpha Emitters, and Brachytherapy Isotopes. The alpha emitters segment dominated the market.

Nuclear Medicine/Radiopharmaceuticals Market, By Geography

• North America
• Europe
• Asia Pacific
• Rest of the world

Based on regional analysis, the Global Nuclear Medicine/Radiopharmaceuticals Market is classified into North America, Europe, Asia Pacific, and the Rest of the world. The largest share in the market will be dominated by North America. The dominance of the North American region can be attributed to the development of novel technologies for radioscopic production and an increase in government funding.

Key Players

• The "Global Nuclear Medicine/Radiopharmaceuticals Market" study report will provide valuable insight with an emphasis on the global market. The major players in the market are
• Cardinal Health, Inc., Mallinckrodt PLC, GE Healthcare (A Fully-Owned Subsidiary of General Electric Company), Lantheus Medical Imaging, Inc., Bayer AG, Bracco Imaging S.P.A, Eczacibasi-Monrol Nuclear Products, Nordion, Inc. (A Subsidiary of Sterigenics International LLC.), Advanced Accelerator Applications S.A., Iba Molecular.
• These major players have adopted various organic as well as inorganic growth strategies such as mergers & acquisitions, new product launches, expansions, agreements, joint ventures, partnerships, and others to strengthen their position in this market.

Key Developments

• Partnerships, Collaborations and Agreements
• A manufacturing and distribution deal was signed in 2019 between Eczacba-Monrol and Telix Pharmaceuticals Limited (Australia). Telix has engaged Eczacba-Monrol as a radiopharmaceutical production partner and distributor throughout Turkey, the Middle East, and North Africa, according to the conditions of the agreement.
• Mergers and Acquisitions
• In the year 2019, Curium acquired MAP Medical, allowing it to expand its footprint in Europe and gain direct access to the Nordic and Baltic countries.
• Product Launches and Product Expansions
• Curium (France) and NRG (Netherlands) inked a Molybdenum-99 manufacturing agreement in 2019.
• Cobalt-60 was purchased from the Board of Radiation and Isotope Technology (BRIT) in April 2019 for distribution throughout Europe by Nordion, Inc.

TABLE OF CONTENTS

1 INTRODUCTION OF GLOBAL NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET

• 1.1 Overview of the Market
• 1.2 Scope of Report
• 1.3 Assumptions

2 EXECUTIVE SUMMARY

3 RESEARCH METHODOLOGY OF VERIFIED MARKET RESEARCH

• 3.1 Data Mining
• 3.2 Validation
• 3.3 Primary Interviews
• 3.4 List of Data Sources

4 GLOBAL NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET OUTLOOK

• 4.1 Overview
• 4.2 Market Dynamics
  • 4.2.1 Drivers
  • 4.2.2 Restraints
  • 4.2.3 Opportunities
• 4.3 Porters Five Force Model
• 4.4 Value Chain Analysis

5 GLOBAL NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET, BY APPLICATION

• 5.1 Overview
• 5.2 Diagnostic Applications
  • 5.2.1 SPECT Applications
  • 5.2.1.1 Cardiology
  • 5.2.1.2 Neurology
  • 5.2.1.3 Thyroid
• 5.3 Other SPECT Applications
  • 5.3.1 PET Applications
  • 5.3.1.1 Oncology
  • 5.3.1.2 Cardiology
  • 5.3.1.3 Neurology
  • 5.3.1.4 Other PET Applications
  • 5.3.2 Therapeutic Applications
  • 5.3.3 Thyroid
  • 5.3.4 Bone Metastasis
  • 5.3.5 Lymphoma
  • 5.3.6 Endocrine Tumors
  • 5.3.7 Other Therapeutic Applications

6 GLOBAL NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET, BY PROCEDURAL VOLUME

• 6.1 Overview
• 6.2 Diagnostic Procedures
  • 6.2.1 SPECT Radiopharmaceuticals
  • 6.2.2 PET Radiopharmaceuticals
• 6.3 Therapeutic Procedures
  • 6.3.1 Beta Emitters
  • 6.3.2 Alpha Emitters
  • 6.3.3 Brachytherapy Isotopes

7 GLOBAL NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET, BY TYPE

• 7.1 Overview
• 7.2 Diagnostic Nuclear Medicine
  • 7.2.1 SPECT Radiopharmaceuticals
  • 7.2.1.1 Tc-99m
  • 7.2.1.2 Tl-201
  • 7.2.1.3 Ga-67
  • 7.2.1.4 I-123
  • 7.2.1.5 Other SPECT Isotopes
• 7.3 PET Radiopharmaceuticals
  • 7.3.1 F-18
  • 7.3.2 Rubidium-82
  • 7.3.3 Other PET Isotopes
• 7.4 Therapeutic Nuclear Medicine/ Radiopharmaceuticals
  • 7.4.1 Beta Emitters
  • 7.4.1.1 Iodine-131
  • 7.4.1.2 Y-90
  • 7.4.1.3 Sm-153
  • 7.4.1.4 Re-186
  • 7.4.1.5 Lu-177
  • 7.4.1.6 Other Beta Emitters
  • 7.4.2 Alpha Emitters
  • 7.4.2.1 Ra-223
  • 7.4.3 Brachytherapy Isotopes
  • 7.4.3.1 Iodine-125
  • 7.4.3.2 Iridium-192
  • 7.4.3.3 Palladium-103
  • 7.4.3.4 Cesium-131
  • 7.4.3.5 Other Brachytherapy Isotopes

8 GLOBAL NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET, BY GEOGRAPHY

• 8.1 Overview
• 8.2 North America
  • 8.2.1 U.S.
  • 8.2.2 Canada
  • 8.2.3 Mexico
• 8.3 EuropeRegional
  • 8.3.1 Germany
  • 8.3.2 U.K.
  • 8.3.3 France
  • 8.3.4 Rest of Europe
• 8.4 Asia Pacific
  • 8.4.1 China
  • 8.4.2 Japan
  • 8.4.3 India
  • 8.4.4 Rest of Asia Pacific
• 8.5 Rest of the World
  • 8.5.1 Latin America
  • 8.5.2 Middle East & Africa

9 GLOBAL NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET COMPETITIVE LANDSCAPE

• 9.1 Overview
• 9.2 Company Market Ranking
• 9.3 Key Development Strategies

10 COMPANY PROFILES

• 10.1 Cardinal Health, Inc.
  • 10.1.1 Overview
  • 10.1.2 Financial Performance
  • 10.1.3 Product Outlook
  • 10.1.4 Key Developments
• 10.2 Mallinckrodt PLC
  • 10.2.1 Overview
  • 10.2.2 Financial Performance
  • 10.2.3 Product Outlook
  • 10.2.4 Key Developments
• 10.3 GE Healthcare (A Fully-Owned Subsidiary of General Electric Company)
  • 10.3.1 Overview
  • 10.3.2 Financial Performance
  • 10.3.3 Product Outlook
  • 10.3.4 Key Developments
• 10.4 Lantheus Medical Imaging, Inc.
  • 10.4.1 Overview
  • 10.4.2 Financial Performance
  • 10.4.3 Product Outlook
  • 10.4.4 Key Developments
• 10.5 Bayer AG
  • 10.5.1 Overview
  • 10.5.2 Financial Performance
  • 10.5.3 Product Outlook
  • 10.5.4 Key Developments
• 10.6 Bracco Imaging S.P.A
  • 10.6.1 Overview
  • 10.6.2 Financial Performance
  • 10.6.3 Product Outlook
  • 10.6.4 Key Developments
• 10.7 Eczacibasi-Monrol Nuclear Products
  • 10.7.1 Overview
  • 10.7.2 Financial Performance
  • 10.7.3 Product Outlook
  • 10.7.4 Key Developments
• 10.8 Nordion, Inc. (A Subsidiary of Sterigenics International LLC.)
  • 10.8.1 Overview
  • 10.8.2 Financial Performance
  • 10.8.3 Product Outlook
  • 10.8.4 Key Developments
• 10.9 Advanced Accelerator Applications S.A.
  • 10.9.1 Overview
  • 10.9.2 Financial Performance
  • 10.9.3 Product Outlook
  • 10.9.4 Key Developments
• 10.10 Iba Molecular
  • 10.10.1 Overview
  • 10.10.2 Financial Performance
  • 10.10.3 Product Outlook
  • 10.10.4 Key Developments

11 Appendix

• 11.1 Related Reports

관련자료